Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(17/week)
Canada
(12/week)
Haiti
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
View all
(29/week)
News
United States
(1301/week)
Manufacturing
(724/week)
Energy
(519/week)
Technology
(1265/week)
Other Manufacturing
(494/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Tyrosine kinase inhibitors
Jun 22, 2020
ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA
Jun 21, 2020
Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors
Jun 12, 2020
EHA25Virtual: Advances in Treatment of High Risk Chronic Lymphocytic Leukemia
Jun 11, 2020
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
May 19, 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
May 14, 2020
Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress
Apr 22, 2020
CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointestinal stromal tumor indications
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Apr 21, 2020
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Mar 28, 2020
Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia
Mar 19, 2020
Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer
Mar 09, 2020
Ascentage Pharma Announces Clearances for Three Phase Ib/II Clinical Studies of APG-2575 in China and the U.S., Beginning Simultaneous Clinical Development in Three Hematologic Malignancy Indications
Feb 27, 2020
Chronic Lymphocytic Leukemia Market, Forecast to 2025 - Roche, AstraZeneca, Verastem, Novartis, and AbbVie are Dominating
Feb 26, 2020
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Jan 14, 2020
Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Jan 08, 2020
New Treatment Approved in Canada for Most Common Type of Leukemia
Dec 13, 2019
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Dec 07, 2019
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Dec 07, 2019
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
Page 1
››
Latest News
Jul 27, 2024
LuxCreo Expands Partnership with ASICS to Make Personalized Shoes Accessible to Everyone
Jul 27, 2024
Smith Foundry Shutting Down Minnesota Facility
Jul 27, 2024
Fonon Corporation Quartz Laser Welding Benefits Glass Manufacturers
Jul 27, 2024
Pioneer Power Announces Filing of Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023
Jul 27, 2024
Kim calls for 'people's paradise' on Korean War anniversary
Jul 27, 2024
Philippines says 'no incidents' as it resupplies hotspot reef
Jul 27, 2024
Alliance Resource Partners, L.P. Declares Quarterly Distribution of $0.70 Per Unit; Announces Robinson...
Jul 27, 2024
EnerSys Completes Acquisition Of Bren-Tronics To Expand Presence In Critical Defense Applications
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
View All Events